Table 3 Major toxicities – WHO criteria (N=55)

From: A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer

 

Number of patients (%)

Toxicity

Grade 1/2

3

4

Neutropenia

13 (23.6)

8 (14.5)

4 (7.3)

Thrombocytopenia

2 (3.6)

1 (1.8)

1 (1.8)

Anemia

16 (29.1)

5 (9.1)

1 (1.8)

Mucositis

3 (5.4)

0

2 (3.6)

Diarrhea

15 (27.3)

2 (3.6)

2 (3.6)

Nausea/vomiting

15 (27.3)

2 (3.6)

1 (1.8)

Hepatotoxicity

2 (3.6)

2 (3.6)

0

Hand–foot syndrome

6 (10.9)

3(5.5)

—

Alopecia

14 (25.5)

3 (5.5)

0

Fever

6 (10.9)

0

0

Nephropathy

1 (3.8)

0

0

Neuropathy

2 (3.6)

0

0

Fatigue

1 (1.9)

2 (3.6)

1 (1.8)

Colitis

0

2 (3.6)

0

Constipation

2 (3.6)

0

0

Infection

0

2 (3.6)

0

Back to article page